CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host
its first quarter 2019 investor update conference call and webcast at
8:30 a.m. Eastern Time on Thursday, May 2, 2019. Individuals interested
in participating in the call should dial (866) 393-4306 (U.S. and
Canada) or (734) 385-2616 (international) using conference ID number
8429338. To access the webcast, please visit the Investors section of
Ironwood’s website at www.ironwoodpharma.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
The call will be available for replay via telephone starting May 2, 2019
at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m.
Eastern Time on May 16, 2019. To listen to the replay, dial (855)
859-2056 (U.S. and Canada) or (404) 537-3406 (international) using
conference ID number 8429338. The archived webcast will be available on
Ironwood’s website for 14 days beginning approximately one hour after
the call has completed.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
(Nasdaq: IRWD) is a GI-focused healthcare company focused on creating
medicines that make a difference for patients living with GI diseases.
We discovered, developed and are commercializing linaclotide, the U.S.
branded prescription market leader for adults with irritable bowel
syndrome with constipation (IBS-C) or chronic idiopathic constipation
(CIC). We are currently advancing a Phase IIIb trial evaluating the
efficacy and safety of linaclotide on multiple abdominal symptoms,
including bloating, pain, and discomfort, in adult patients with IBS-C.
We are also advancing two late-stage, first-in-category GI product
candidates: IW-3718 is a gastric retentive formulation of a bile acid
sequestrant being developed for the potential treatment of persistent
gastroesophageal reflux disease, and MD-7246 is a delayed-release
formulation of linaclotide that is being evaluated as an oral,
intestinal, non-opioid, pain-relieving agent for patients suffering from
abdominal pain associated with IBS with diarrhea.
Ironwood was founded in 1998 and is headquartered in Cambridge, Mass.
For more information, please visit our newly launched website at www.ironwoodpharma.com
or www.twitter.com/ironwoodpharma;
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190418005615/en/
Media and Investors:
Meredith Kaya, 617-374-5082
Vice
President, Investor Relations and Corporate Communications
mkaya@ironwoodpharma.com
Source: Ironwood Pharmaceuticals, Inc.